CRISPR Therapeutics Proposes Changes to the Board of Directors
26 Febrero 2020 - 3:05PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced it proposes to elect Doug Treco, Ph.D. to
its Board of Directors at the Company’s upcoming annual general
meeting to be held later this year. The Company also announced that
Pablo Cagnoni, M.D., Chief Executive Officer of Rubius
Therapeutics, will resign from the Board of Directors to focus on
other commitments, effective immediately.
“On behalf of our Board of Directors and
management team, I would like to thank Pablo for his years of
service and his many contributions to CRISPR Therapeutics, and I
wish him the best in his future endeavors,” said Rodger Novak,
M.D., President and Chairman of the Board of CRISPR Therapeutics.
“We are grateful for his thoughtful guidance and support over the
years.”
Dr. Novak added: “We are excited to invite Doug
to our Board during an important time in CRISPR Therapeutics’
continued evolution. He has an impressive track record of success
in advancing the development of numerous drug candidates, with a
unique focus on rare disease, gene targeting, and gene therapy. His
deep expertise and leadership experience will make him an
outstanding addition to our Board, and we look forward to the
valuable insights he will bring.”
Doug co-founded Ra Pharmaceuticals, Inc.
(Nasdaq: RARX) in 2008 and has been Chief Executive Officer and a
member of the Board of Directors since its inception. Ra Pharma is
a leader in macrocyclic peptide and small molecule therapeutics
targeting the complement pathway and has advanced its lead
molecule, zilucoplan, into the clinic for multiple neuromuscular
indications, including an ongoing pivotal Phase 3 study in
myasthenia gravis. In October 2019, Ra Pharma entered into a merger
agreement with UCB pursuant to which UCB will acquire Ra Pharma. He
was an Entrepreneur-in-Residence at Morgenthaler Ventures from
January 2008 to May 2014. In 1988, Doug co-founded Transkaryotic
Therapies Inc. (TKT), a multi-platform biopharmaceutical company
developing protein and gene therapy products, where he led the
discovery of a number of approved biopharmaceuticals, including
Dynepo™, Replagal®, Elaprase®, and Vpriv®. TKT (formerly
Nasdaq: TKTX) was acquired by Shire Pharmaceuticals Group plc in
2005. He was a Visiting Scientist in the Department of
Molecular Biology at Massachusetts General Hospital and a Lecturer
in Genetics at Harvard Medical School from 2004 to 2007. Doug
received his Ph.D. in Biochemistry and Molecular Biology from the
State University of New York at Stony Brook and performed
postdoctoral studies at the Salk Institute for Biological Studies
and Massachusetts General Hospital.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
partnerships with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in San Francisco,
California and London, United Kingdom. For more information, please
visit www.crisprtx.com.
Important Additional Information and
Where to Find It CRISPR Therapeutics will file a
proxy statement with the United States Securities and Exchange
Commission (“SEC”) in connection with the solicitation of
proxies for its 2020 annual general meeting (“2020 Annual
Meeting”). SHAREHOLDERS ARE STRONGLY ADVISED TO READ THE PROXY
STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN
IMPORTANT INFORMATION. Shareholders may obtain a free copy of the
proxy statement, any amendments or supplements to the proxy
statement and other documents that CRISPR Therapeutics files
with the SEC from the SEC’s website
at www.sec.gov or CRISPR Therapeutics’ website
at www.crisprtx.com as soon as reasonably practicable
after such materials are electronically filed with, or furnished
to, the SEC.
Certain Information Regarding
ParticipantsCRISPR Therapeutics, its directors, nominees
for election as director, executive officers and other persons
related to CRISPR Therapeutics may be deemed to be
participants in the solicitation of proxies from CRISPR
Therapeutics’ shareholders in connection with the matters to be
considered at the 2020 Annual Meeting. Information concerning the
interests of CRISPR Therapeutics’ participants in the solicitation
is set forth in the materials filed by CRISPR Therapeutics
with the SEC, including in its definitive proxy statement
filed with the SEC on April 30, 2019, and will be
set forth in the proxy statement relating to the 2020 Annual
Meeting when it becomes available.
Investor Contact:Susan
Kimsusan.kim@crisprtx.com
Media Contact:Rachel EidesWCG
on behalf of CRISPR617-337-4167 reides@wcgworld.com
Transkaryotic Therapies (NASDAQ:TKTX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024